BBANTWi007-A

iPSC_BrS10_FB_C3

General

Cell Line

hPSCreg name BBANTWi007-A
Cite as:
BBANTWi007-A (RRID:CVCL_B3NM)
Alternative name(s)
iPSC_BrS10_FB_C3
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BBANTWi006-A
(iPSC_BrS9_FB_C7)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome 1
UKKi030-A
(NP0134-6D)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome
UKKi030-B
(NP0134-18A)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome
UKKi030-C
(NP0134-26B)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome
CBRCULi016-A
(SCN5A p.R219H-14C)
Donor's gene variants:
SCN5A
Donor diseases:
dilated cardiomyopathy
CBRCULi016-A-1
(SCN5A p.R219H-14C-ISO)
Donor's gene variants:
SCN5A
Donor diseases:
dilated cardiomyopathy
CIAUi002-C
(UBC3 M1)
Donor's gene variants:
SCN5A, SCN5A
Donor diseases:
Left bundle branch block
nonischemic cardiomyopathy
UKKi008-A
(NP0016-3)
Donor's gene variants:
SCN5A
Donor diseases:
Familial long QT syndrome
LUMCi027-A
(LUMC0153iPKP03)
Donor's gene variants:
PKP2
Donor diseases:
arrhythmogenic right ventricular dysplasia 9
UTSWi003-A
(FA3)
Donor's gene variants:
fxn
Donor diseases:
Friedreich Ataxia
LUMCi030-B
(LUMC0110iALK10)
Donor diseases:
Hereditary Hemorrhagic Telangiectasia
TAUi005-A
(UTA.14511.CPVT)
Donor's gene variants:
RYR2
Donor diseases:
Catecholaminergic polymorphic ventricular tachycardia
TAUi006-A
(UTA.00102.LQT1)
Donor's gene variants:
KCNQ1 – potassium voltage-gated channel subfamily Q member 1
Donor diseases:
Long QT Syndrome 1
TAUi006-B
(UTA.00118.LQT1)
Donor's gene variants:
KCNQ1 – potassium voltage-gated channel subfamily Q member 1
Donor diseases:
Long QT Syndrome 1
TAUi007-A
(UTA.00208.LQT1)
Donor's gene variants:
KCNQ1 – potassium voltage-gated channel subfamily Q member 1
Donor diseases:
Long QT Syndrome 1
TAUi007-B
(UTA.00211.LQT1)
Donor's gene variants:
KCNQ1 – potassium voltage-gated channel subfamily Q member 1
Donor diseases:
Long QT Syndrome 1
LUMCi030-A
(LUMC0110iALK04)
Donor diseases:
Hereditary Hemorrhagic Telangiectasia
ICANi001-A
(CDGEN1.16)
Donor diseases:
hypertrophic cardiomyopathy
RCMGi002-A
(P7L2)
Donor diseases:
Cystic Fibrosis
RCMGi008-A
(P9L1)
Donor diseases:
Cystic Fibrosis
UMCGi002-A
(CTP1-C1)
Donor diseases:
Cardiomyopathy
UMCGi002-B
(CTP1-C2)
Donor diseases:
Cardiomyopathy
RCMGi007-A
(P8L2)
Donor diseases:
Cystic Fibrosis
UMCGi002-C
(CTP1-C3)
Donor diseases:
Cardiomyopathy
MHRCCGi001-A
(P1SH)
Donor diseases:
Schizophrenia
Last update 13th December 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Biobank Antwerpen (BBANTW)
Owner Center of Medical Genetics Antwerp (CMGANT)
Distributors
Derivation country Belgium

External Databases

BioSamples SAMEA11423532
Cellosaurus CVCL_B3NM
Wikidata Q110432591

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Ethnicity White Belgian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • BRGDA1
Genetic variants
SCN5A (target)
3p22.2
NM_198056.3:c.4813+3_4813+6dupGGGT
Heterozygous
PMID: 33221854
Disease associated phenotypes
  • Spontaneous BrS type 1 ECG
Family history yes
Is the medical history available upon request? available upon request
Is clinical information available? available upon request

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46, XX. No clinically significant abnormalities observed.
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes
SNP typing array
Skin fibroblast DNA sample was genotyped with Illumina's HumanCytoSNP-12 v2.1. No clinically significant CNVs observed.

External Databases (Donor)

BioSamples SAMEA11423533

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Study of inherited cardiovascular diseases
Does consent permit unforeseen future research, without further consent? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Through the treating physician
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? UZA ethics committee
Approval number EC 16/49/537
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? UZA ethics committee
Approval number EC 16/49/537
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? CytoTune™-iPS 2.0 Sendai Reprogramming Kit from Invitrogen / ThermoFisher Scientific
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Source cell origin
Source cell type (free text) Skin biopsy was taken on inner side of upper arm
Passage number reprogrammed 3

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Notes on reprogramming vector detection SeV not detected on passage 11

Vector free reprogramming

Other

Selection criteria for clones Clones were picked based on morphology (round, flat colonies with smooth edges and tightly packed cells) for 5 rounds and subsequently passaged using EDTA for 5 more rounds. Only clones with nice morphology and no differentiation after these 10 passaging rounds were selected.
Derived under xeno-free conditions
No
Derived under GMP?
Unknown
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Essential 8™ Flex
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
TRA 1-81
Yes
NANOG
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
SOX17
Yes
CXCR4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
DCN
Yes
VIM
Yes
HEY1
Yes
IGF2
Yes
Cardiac Muscle Cell
Ont Id: CL_0000746
In vitro directed differentiation
Marker Expressed
Troponin I, cardiac muscle
Yes
SCN5A
Yes
alpha-actinin 2
Yes
NKX2-5
Yes
MYL2
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
PAX6
Yes
HES5
Yes
MAP2
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX. No clinically significant abnormalities observed.
Passage number: 11
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
SNP typing array
Genotyped with Illumina's HumanCytoSNP-12 v2.1. No clinically significant CNVs observed.